Share your videos with the world

Ahead of World Mental Health Day, today sees the publication of the Mental Health Integration Index, a new research initiative commissioned by the Janssen Pharmaceutical Companies of Johnson & Johnson and undertaken by the Economist Intelligence Unit.1 The research explores the challenges of integrating Europeans with mental illness into society and employment, within the European Union’s 28 Member States, plus Norway and Switzerland. Countries have been ranked according to their degree of commitment to support those living with mental illness; the findings demonstrate that while there are many examples of good practice across Europe, the whole region has a long way to go before people with mental illness are adequately supported and truly integrated into their communities. To view the Multimedia News Release, go to: http://www.multivu.com/players/English/72762557-janssen-europe-mental-health-index/

The sixth annual Productive Innovation Index released by IDEA Pharma today, which ranks biopharmaceutical companies by their ability to successfully bring innovations to market, sees Johnson & Johnson top the industry for the fourth year running. The Productive Innovation Index measures, scores and celebrates a company’s ability to deliver innovation to patients, by objectively evaluating performance data based on a rolling five year period (2010-2015), and operates on the premise: if you gave the same molecule to two different companies in early phase, which would make the best of it? The success of the Janssen Pharmaceutical Companies of Johnson & Johnson and its consolidation of 1st place across the past four years’ rankings is driven largely by innovations in the field of oncology, immunology, neuroscience and cardiovascular/metabolism. Notable performers include Zytiga® (prostate cancer), Imbruvica® (chronic lymphocytic leukemia and mantle cell lymphoma (co-developed and co-marketed with Pharmacyclics, an AbbVie company)), Simponi®/Simponi Aria® (rheumatoid arthritis), Stelara® (psoriasis and psoriatic arthritis), Invega Sustenna® and Invega Trinza® (schizophrenia). To view the multimedia release go to: http://www.multivu.com/players/uk/7770851-johnson-and-johnson-tops-idea-pharma/